SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

PTX80

Item No. 41676

CAS Registry No.:	2376297-69-5
Formal Name:	4,4'-((1E,1'E)-(1-((3-(dimethylamino)propyl) sulfonyl)-4-oxopiperidine-3,5-diylidene) *bis*(methaneylylidene))dibenzonitrile
MF:	$C_{26}H_{26}N_4O_3S$
FW:	474.6
Purity:	≥95%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PTX80 is supplied as a solid. A stock solution may be made by dissolving the PTX80 in the solvent of choice, which should be purged with an inert gas. PTX80 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in acetonitrile.

Description

PTX80 is an antagonist of p62 (IC_{50} = 31.18 nM for the human receptor).[1] It decreases the soluble fraction of p62 in MM.1S multiple myeloma cells when used at a concentration of 1.5 µM. PTX80 (200 nM) increases the levels of polyubiquitinated proteins in MM.1S cells. It induces apoptosis in MM.1S cells when used at a concentration of 100 nM. PTX80 (50-400 nM) decreases the survival of $CD138^+$ cells, but not $CD138^-$ cells, in primary plasma cells derived from patients with multiple myeloma. It reduces the viability of tumor tissue samples isolated from ten patient-derived xenograft (PDX) mouse models of colorectal cancer (IC_{50}s = 113-1,220 nM). *In vivo*, PTX80 (8 or 12 mg/kg twice per week) reduces tumor volume in an HCT116 colorectal cancer mouse xenograft model.

Reference

1. Kalid, O., Gotliv, I., Levy-Apter, E., *et al.* PTX80, a novel compound targeting the autophagy receptor p62/SQSTM1 for treatment of cancer. *Chem. Biol. Drug Des.* **100(5)**, 623-638 (2022).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM